|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data reveal competition between two proto-oncogenes, MYC and AKT, which ensnarls the Phlpp2 gene to facilitate MYC-driven prostate cancer metastasis after loss of Pten and Trp53.
|
25829425 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results implicate a role for amplification of androgen receptor in hormonal therapy failure and that of MYC in the metastatic progression of human prostate cancer.
|
10029066 |
1999 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The developed array biochip is then utilized to parallelly analyze the O-GlcNAcylation of three oncogenic transcription factors C-Myc, NF-κB and p53 in normal prostate epithelial cell (RWPE-1) and prostate cancer cell line (PC-3).
|
30086259 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
|
21685943 |
2012 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.
|
25115192 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage.
|
16310933 |
2006 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A long-range interaction of genetic variants with c-MYC or long non-coding PVT1 at this locus contributes to the genetic risk of prostate cancer.
|
30808975 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cooperative oncogenic effects resulting from the loss of PTEN and overexpression of MYC overcome the deleterious effects of endoplasmic reticulum stress not only to promote the growth of aggressive prostate cancer but also to expose a new therapy target for this disease (Nguyen <i>et al</i>, this issue).
|
29720450 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we provide an overview of the transcription factors that are important in normal prostate homeostasis (NKX3-1, p63, androgen receptor [AR]), primary prostate cancer (ETS family members, c-MYC), castration-resistant prostate cancer (AR, FOXA1), and AR-independent castration-resistant neuroendocrine prostate cancer (RB1, p53, N-MYC).
|
29530947 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.
|
20627891 |
2010 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP).
|
28888037 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
|
26347108 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
|
28202510 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data demonstrate that <sup>68</sup>Ga-citrate targets prostate cancer tumors with MYC hyperactivity.
|
28592703 |
2017 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we highlight a new mechanism by which USP2a enhances MYC levels through the modulation of specific subsets of microRNAs in prostate cancer, suggesting alternative therapeutic strategies for targeting MYC.
|
22585994 |
2012 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exposure of prostate cancer cells to plasma achievable doses of HNK resulted in a marked decrease in levels of total and/or phosphorylated c-Myc protein as well as its mRNA expression.
|
27341160 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the expression levels of TRPS1, EIF3S3 and MYC were measured in freshly frozen clinical samples of benign prostate hyperplasia (BPH), as well as untreated and hormone-refractory prostate carcinoma.
|
14997205 |
2004 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> There are several studies relating immunohistochemical markers with clinical-laboratorial outcomes in prostate cancer, the most frequent being Ki-67, p53, ERG, PTEN, and MYC.
|
30280090 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because c-MYC and AR signaling are essential for prostate cancer initiation and progression, we aim to test whether targeting Plk1 and BRD4 at the same time is an effective approach to treat prostate cancer.
|
29716963 |
2018 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sphere formation and side population assays suggested that miR-1301-3p promoted the expansion of prostate cancer stem cells, and increased the expression of prostate cancer stem cell-associated genes, such as OCT4, SOX2, NANOG, CD44, KLF4, c-MYC, and MMP2.
|
29358129 |
2018 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data indicate that three well-established oncogenic drivers (AR, MYC, and mTOR) function by converging to collectively increase the expression of glutamine transporters, thereby promoting glutamine uptake and subsequent prostate cancer cell growth.<b>Implications:</b> AR, MYC, and mTOR converge to increase glutamine uptake and metabolism in prostate cancer through increasing the levels of glutamine transporters.<i></i>.
|
28507054 |
2017 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the expression levels of IRS2 and MYC were highly correlated in human prostate cancer, and IRS2 could stimulate MYC expression in cultured cells.
|
19095950 |
2009 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
|
19773438 |
2009 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer PC3 cells were transfected with LXR-a siRNA and treated with LXR activator T0901317. qRT-PCR and western blot were used to detect the LXR-a expression. beta-catenin, cyclin D1 and c-MYC were analyzed by western blot.
|
28139275 |
2017 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
|
20820186 |
2010 |